The biologically active circulating form of atrial natriuretic factor (ANF) in the rat is the 28-amino-acid peptide ANF- . Degradation ofthis peptide in vivo as well as in vitro, in whole blood, in plasma and by the isolated mesenteric artery was investigated. Studies in vivo in the rat demonstrated that the elimination and degradation of ANF was extremely fast: within 3 min more than 95% of the injected immunoreactive material was eliminated from circulation. The production of a short C-terminal peptide was detected on injection of 1251I-ANF-(Ser-99-Tyr-126) into the rat. This peptide increased proportionately with incubation time. Experiments in vitro in the presence of whole blood or plasma did not cause any major destruction of ANF even after incubation for 60 min. After this prolonged incubation in plasma, ANF-(Ser-99-Tyr-126) was partially converted into ANF-(Ser-103-Tyr-126), a less potent peptide. Isolated mesenteric-artery preparation appeared to degrade ANF in a manner very similar to the system in vivo. These results suggest that degradation of ANF may occur either after internalization in the vascular cells or by a membrane-bound enzyme in the vasculature.
INTRODUCTION
Atrial natriuretic factor (ANF) is a peptide hormone with potent natriuretic and diuretic [1] and vasorelaxant [2, 3, 4] properties. This is stored in specific granules in mammalian cardiocytes [5] [6] [7] [8] as its precursor molecule [9, 10] . The biologically active circulating form of this hormone, however, is the 28-amino-acid peptide ANF-(Ser-99-Tyr-126) [11, 12] , the sequence of which is given below:
had specific radioactivities of 200-300,Ci/,ug peptide.
of Collection of blood
Blood was withdrawn from the abdominal aorta of male Sprague-Dawley rats anaesthetized with sodium pentobarbital (60 mg/kg, intraperitoneally) and collected into pre-chilled Vacutainer tubes containing either Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-ArgIle-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr
Even though extensive work is being done on the biological effects of this hormone (for reviews see [13] [14] [15] ), not much attention has been paid to its degradation. Our previous study on the disappearance of 125I-ANF peptides from circulation of the rat indicated an extremely rapid elimination of radioactive peptide from the system [16] . In an effort to understand the nature of this degradation/elimination process, the present study was undertaken. ANF-(Ser-99-Tyr-126) and its radioiodinated form were injected into the rat, blood samples were withdrawn at different time intervals
and the products present in circulation were analysed. The degradation of this peptide hormone in whole blood and plasma as well as in the isolated perfused mesenteric artery was also studied.
MATERIALS AND METHODS Materials ANF-(Ser-103-Tyr-126), ANF-(Arg-101-Tyr-126) and ANF-(Ser-99-Tyr-126) were purchased from Armand Frappier (Laval, Quebec, Canada). ANF-(Glu-54-Tyr-126) and ANF-(Asn-l-Tyr-126) were purified from rat atria as reported elsewhere [17, 18] . The peptides were iodinated by the lactoperoxidase method and later purified by reverse-phase h.p.l.c. [16] . The preparations Abbreviation used: ANF, atrial natriuretic factor. * To whom correspondence should be addressed.
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EDTA or heparin as anticoagulant. Plasma was separated by centrifugation at 3500 rev./min for 20 min at 4°C and stored on ice until used.
H.p.l.c. separation
Samples dissolved in 10% (v/v) acetonitrile in 0.1 % trifluoroacetic acid were loaded on a Cl8,uBondapak column (0.39 mm x 30 mm) and eluted with a linear gradient of 1540% acetonitrile in 0.1 % trifluoroacetic acid at a flow rate of 1 ml/min and a slope of 0.5% /min. Fractions were collected every 1 min and counted for radioactivity in an LKB gamma counter. For nonradioactive samples, the elution was monitored at 210 nm with an on-line u.v. detector. Molecular-sieve h.p.l.c. was performed on a BioSil TSK-125 column (0.75 cm x 60 cm) by using a Varian 5060 liquid-chromatograph system. The peptides were eluted isocratically at 0.5 ml/min with 30% (v/v) CH3CN containing 0.2 M-NaCl and 0.1 % trifluoroacetic acid. The column was calibrated with radioiodinated ANF peptides, ANF-(Ser-99-Tyr-126), ANF-(Glu-54-Tyr-126) and ANF-(Asn-l-Tyr-126). Fractions were collected every 0.3 min and counted for radioactivity in an LKB gamma counter.
Radioimmunoassay
The immunoreactive material in the samples was assayed by using three different antibodies, which recognize different portions of the ANF-(Arg-101-Tyr-126) molecule: anti-(human ANF) antibody (Peninsula Laboratories, Belmont, CA, U.S.A.), which recognizes the C-terminus [19] , anti-(rat ANF) antibody, which recognizes the mid portion of the molecule [20] , and a monoclonal antibody which recognizes the N-terminal portion [21] . The radioimmunoassays were done as outlined in the respective references.
Degradation studies in vivo
Male Sprague-Dawley rats (200-250 g) were anaesthetized with sodium pentobarbital (60mg/kg, intraperitoneally), and the left carotid artery and right jugular vein were cannulated with PE-50 catheters.
ANF-(Ser-99-Tyr-126) (5 and 10,g) was injected into the jugular vein, with heparinized (100 units/ml) saline containing 0.01 % bovine serum albumin as vehicle. The total volume of each injection was 200 ,l. Blood samples (approx. 500,l) were collected through the carotid artery at timed intervals, as indicated in Fig. 1 , directly into Eppendorf tubes kept on ice and immediately centrifuged in an Eppendorf centrifuge at 4 'C. Plasma (200 ll) was added to an equal volume of 8% (v/v) acetic acid, loaded on a C18 Sep-Pak cartridge (Waters Associates), and ANF was extracted by the method of Lang et al. [22] . The extraction is based on the principle that ANF and shorter peptides bind to the C18 matrix of the cartridge by hydrophobic interaction. Non-specifically adsorbed material, representing mostly salt (including 1251), and free amino acids are eliminated by an initial water wash, which is followed by elution ofthe adsorbed material with 86% (v/v) ethanol in 4% acetic acid. A known volume of the eluate was evaporated to dryness on a Speed-Vac concentrator (Savant Instruments), reconstituted in the radioimmunoassay buffer and analysed by radioimmunoassay by using the three different anti-ANF antibodies as outlined above.
In another set of experiments, 125I-ANF-(Ser-99-Tyr-126) was injected into the jugular vein of the rat, with heparinized saline as vehicle, as mentioned above. Blood samples were collected at timed intervals, and ANF was extracted from plasma by using C18 Sep-Pak cartridges and analysed by reverse-phase h.p.l.c.
In a third set of experiments, 1251-ANF-(Ser-99-Tyr-126) (10 x 106 c.p.m.) was injected intrajugularly, and blood (approx. 6 ml) collected between 20 and 25 min into a pre-chilled polystyrene tube. ANF was extracted from the plasma by using C18 Sep-Pak cartridge and analysed by molecular-sieve h.p.l.c. as outlined above. plasma after addition of acetic acid and treated just as the test samples.
Unlabelled ANF. ANF-(Ser-99-Tyr-126) (5 jug) was incubated with 1 ml of plasma (containing EDTA or heparin) for different intervals of time from 15 s to 30 min at 37 'C. A sample (100 ,1) of plasma was removed at the end of each incubation period, and ANF was extracted on a C18 Sep-Pak cartridge and analysed by radioimmunoassay with the three different antibodies as outlined under 'Radioimmunoassay'. As a control, 500 ng of ANF-(Ser-99-Tyr-126) was added to 100 4a1 of plasma after addition of acetic acid and further treated just like the test samples.
In another set of incubation studies, 40 ,g of ANF-(Ser-99-Tyr-126) was incubated with 1 ml of plasma for 5, 30 and 60 min at 37 'C. At the end of each incubation period, a sample (250,l) was extracted on a C18 Sep-Pak cartridge and subjected to reverse-phase h.p.l.c. The peptide elution was monitored at 210 nm and the individual peaks were collected manually. Immunoreactivity of these peaks was checked by using anti-(rat ANF) antibody and the immunoreactive peaks were re-chromatographed (twice) individually on a C8. uBondapak column with a linear gradient of 18-30% CH3CN (slope 0.25% /min) in 0.1 % trifluoroacetic acid. The eluted peptide peaks were monitored at 210 nm and collected manually. Samples collected after Degradation in blood Radiolabelled ANF. 125I-ANF-(Ser-99-Tyr-126) was incubated with whole blood or plasma for 5, 10 and 30 min at 37 'C. A portion of the sample was removed at the end of each incubation period, and ANF was extracted from plasma by using C18 Sep-Pak cartridges and analysed by reverse-phase h.p.l.c. As a control for the whole-blood study, 125I-ANF-(Ser-99-Tyr-126) was added to pre-chilled blood, centrifuged immediately at 4 'C, and the plasma was treated like the test samples. As a control in the incubation studies with plasma, 125I-ANF-(Ser-99-Tyr-126) was added to ANF-(Ser-99-Tyr-126) (5 ,sg) was injected intrajugularly, and 500 #1 blood samples were collected at timed intervals as indicated on the abscissa. ANF was extracted from the plasma by using C18 Sep-Pak cartridges and assayed by radioimmunoassay using the different antibodies as outlined in the Materials and methods section.
*, Anti-(human ANF) antibody (C-terminal); [1, monoclonal antibody (N-terminal); 0, anti-(rat ANF) antibody (mid-portion).
the final fractionation were subjected to amino acid analysis. Known volumes of the eluate containing the peptides were evaporated to dryness on a Speed-Vac concentrator, hydrolysed in 6M-HCI in the presence of 2.5 nmol of norleucine as internal standard and analysed on a Beckman 120C amino acid analyser equipped with a model 126 computing integrator. Studies with isolated perfused mesenteric artery The isolated mesenteric artery was prepared from male Sprague-Dawley rats (200-250 g) by the method of McGregor [23] . The preparation was perfused with oxygenated Krebs buffer at a constant flow of 2 ml/min and maintained at 37°C throughout the experiment. 125I-ANF-(Ser-99-Tyr-126) (10 x 106 c.p.m.) was injected into the vascular bed, and the perfusate was collected at timed intervals directly into vials containing an equal volume of 8% acetic acid kept on ice. ANF peptides were extracted with C18 Sep-Pak cartridges and analysed by reverse-phase h.p.l.c. as outlined above.
RESULTS

Degradation in vivo
Earlier studies on the intravenous injection of 1251-ANF-(Ser-99-Tyr-126) into the rat demonstrated an extremely rapid disappearance, within 1 min, of the labelled peptide from circulation [16] . To see if the disappearance of immunoreactive material paralleled this pattern, ANF-(Ser-99-Tyr-126) (5,g) was injected intrajugularly, blood samples were collected at timed intervals and ANF concentrations in plasma assayed by using three different antibodies which recognize different portions of the ANF-(Arg-101-Tyr-126) molecule. The results of this study are given in Fig. 1 . The immunoreactive material disappeared very quickly from circulation, reaching values less than 5% of the injected dose in about 3 min. After 5 min the values were undetectable. No difference was observed with the three different antibodies. Similar results were obtained when 10 jug of the peptide was injected into the circulation.
After the injection of 125I-ANF-(Ser-99-Tyr-126) into the rat, the radiolabelled peptide fragments present in circulation at different time intervals were studied. The Sep-Pak-adsorbed radioactivity, represented as a percentage of the total (remaining in the blood) loaded on the cartridge, is given in Table 1 radioactive material were observed, one eluted at 17%
CH3CN and the other eluted at the position of the intact peptide. There was a gradual increase in the percentage of the peptide eluted at 17% CH3CN with increasing duration of time in circulation and a concomitant decrease in the proportion of the intact peptide ( Fig. 2 and Table 1 ). In the sample collected after 5 min, only 10% of the radioactive material adsorbed to the Sep-Pak cartridge represented the intact peptide. However, when the value was corrected for the radioactive material in blood (percentage of maximum), it constituted only 1 % (Table 1 ). In the sample collected at 25 min no intact peptide was observed. The peak eluted at 17% CH3CN had no immunoreactivity, whereas the binding of the other peak was similar to that of 1251I-ANF-(Ser-99-Tyr-126) when tested with anti-(rat ANF) antibody.
To verify the nature of the peptide molecule eluted at 17% CH3CN, 125I-ANF-(Ser-99-Tyr-126) was injected intravenously into the rat, blood was collected between 20 and 25 min and the plasma was extracted with a Sep-Pak cartridge. The molecular-sieve h.p.l.c. pattern of the eluate is given in Fig. 3 . The radioactive material was eluted very close to the fractionation limit of the column. A Mr of about 1000 was calculated for this molecule, suggesting it to be only a short C-terminal fragment of the 28-amino-acid peptide. Since tyrosine forms the C-terminus of the ANF peptide, this eluted peptide would represent a C-terminal fragment of ANF-(Ser-99-Tyr-126). The formation of any other short peptide from the N-terminus could not be detected under the conditions used in our study.
Degradation in vitro
Incubation of 1251-ANF-Ser-99-Tyr-126) in whole blood and plasma. There was no significant increase in the radioactive material passing through the Sep-Pak cartridge on incubation of the ANF peptide with whole blood. Only 10% of the radioactive material passed through the cartridge after 30 min of incubation. The h.p.l.c. pattern of the material adsorbed to the cartridge after a 30 min incubation in blood is given in Fig. 4 . 125I-ANF-(Ser-99-Tyr-126) (1 x 106 c.p.m.) was incubated at 37°C with EDTA-containing whole blood (2 ml) for different time intervals. A sample (500 pl) was removed at the end of the incubation period, and ANF was extracted from plasma by using a C18 Sep-Pak cartridge and analysed by reverse-phase h.p.l.c. Incubation of ANF-(Ser-99-Tyr-126) with plasma. Incubation of ANF-(Ser-99-Tyr-126) with plasma resulted in a partial loss of immunoreactivity of the samples over a period of 30 min. As measured with the anti-(human ANF) antibody (Peninsula Laboratories), which recognizes the C-terminus [19] , and the anti-(rat ANF) antibody, which recognizes the mid-portion of the ANF-(Arg-101-Tyr-126) molecule [20] , the loss of immunoreactivity was about 15-20% after 30 min. However, when the samples were assayed with the monoclonal antibody which recognizes the N-terminus of the ANF-(Arg-101-Tyr-126) molecule [21] , the loss of immunoreactivity was about 40-50%. This suggests a partial degradation of the peptide at the N-terminal. Both heparinized plasma and plasma with EDTA gave similar results.
The h.p.l.c. pattern of the material adsorbed to the Sep-Pak cartridge after incubation of ANF-(Ser-99-Tyr-126) with plasma is given in Fig. 5 . The first panel (t = 0 min), which represents the control sample, gave two peaks ofu.v. absorbance, the first being a non-specific absorbance peak from plasma; immunoreactive material was present only in the second peak. After 30 min incubation a third absorbance peak was observed. This peak became pronounced in the 60 min sample, with a proportional decrease in the second peak. No other degradation products were obvious.
The amino acid compositions of the two immunoreactive peaks obtained in plasma degradation studies are given in Table 2 . ANF-(Ser-99-Tyr-126), ANF-(Arg-101-Tyr-126) and ANF-(Ser-103-Tyr-126) were also analysed along with the test samples. The amino acid analysis indicated peak II to be ANF-(Ser-99-Tyr-126) and peak III, the newly formed peak, to be ANF-(Ser-103-Tyr-126). Studies with isolated perfused mesenteric artery After a bolus injection of 1251-ANF-(Ser-99-Tyr-126), most of the radioactivity (approx. 90%) was obtained in the eluate collected in the first 2 min. However, there was a gradual fall in the eluted radioactive material thereafter, continuing up to 30 min (Table 3 ). Samples were collected at different time intervals and extracted by using Sep-Pak cartridges. The radioactivity adsorbed to the Sep-Pak (% of injected sample) is given in Table 3 .
There was a gradual decrease in the amount of Sep-Pak-adsorbed material with increase in incubation time. In the 10-15 min sample, about 50% of the material passed through the Sep-Pak cartridge. The h.p.l.c. elution profile of the Sep-Pak-adsorbed material is given in Fig. 6 . The amount of intact peptide in the samples decreased with time after the bolus injection of radiolabelled peptide ( Fig. 6 and Table 3 ). By 15 min, only 37% of the total radioactivity loaded on the h.p.l.c.
column represented the intact peptide. After correction for the radioactivity passing through the Sep-Pak cartridge, the amount of intact peptide was just 19%. This was further decreased to 13 % after 25 min. The immunoreactivity of this peak with anti-(rat ANF) antibody was similar to that of 1251I-ANF-(Ser-99-Tyr-126). Accompanying this decrease in the intact peptide was a proportionate increase in a radioactive peak eluted at 17% CH3CN. This peak had no immunoreactivity when tested with anti-(rat ANF) antibody.
DISCUSSION
The results of our studies of degradation in vivo by using radiolabelled peptide indicated that ANF-(Ser-99-Tyr-126) was degraded very quickly in the circulation of the rat. By the first 80 s after the peptide injection, less than 50% of the radioactive material remaining in circulation represented the intact peptide. When the value for the percentage of intact peptide in circulation is corrected for the decrease in circulating radioactivity at the time of blood collection, the value is further decreased to 13 %. This is comparable with the decrease in immunoreactive material in circulation observed as a Vol. 240 This extremely fast disappearance of ANF from circulation, accompanied by the rapid degradation observed in vivo, would probably explain the short Table 3 . Degradation of '26I-ANF-(Ser-99-Tyr-126) by the isolated perfused mesenteric artery 1211-ANF-(Ser-99-Tyr-126) (10 x 106 c.p.m.) was injected into an isolated mesenteric-artery preparation perfused with oxygenated Krebs buffer at a flow rate of 2 ml/min. Perfusate samples were collected at timed intervals and the radioactivity was calculated as a percentage of injected dose. ANF was extracted from the perfusate by using C18 Sep-Pak cartridges and subjected to reverse-phase h.p.l.c. The radioactive peak eluted at the position of the intact peptide is represented as a percentage of the total radioactivity loaded on the h.p.l.c. column. This value, corrected for the radioactive material passing through the Sep-Pak cartridge (column 3), is presented in the last column. duration of the biological response in vivo observed by de Bold et al. [1] , and subsequently by Garcia et al. [6] and Ackermann and co-workers [24] . However, from those studies it is difficult to single out any particular organ as being responsible for this rapid disappearance process, since receptors for ANF have been localized in a large number of organs of the rat [25] .
There have been several reports in the literature on ANF metabolism in blood. The conversion of the propeptide [ANF-(Asn-1-Tyr-126)] into the active form by rat serum has been reported by Bloch et al. [26] and Glembotski & Gibson [27] . Another group [28] has reported the degradation of low-Mr ANF. However, the degradation products have not been characterized. Since
Vol. 240 ANF-(Ser-99-Tyr-126) has now been identified in the circulation of the rat [11, 12] , it was of interest to see if it is degraded in blood. The results of our study indicate that ANF-(Ser-99-Tyr-126) is converted very slowly by a plasma proteinase into a 24-amino-acid form, ANF-(Ser-103-Tyr-126). This would probably account for the presence of ANF-(Ser-103-Tyr-126) as a minor form in the circulation of the rat, as reported by Schwartz et al. [12] . In an earlier study Veress et al. [28] followed the inactivation of low-Mr ANF in blood by measuring the decrease in diuretic and natriuretic response. They observed a decrease of 50% in the activity after a 60 min incubation with whole blood or a platelet-rich fraction. However, no degradation was observed in either plasma or the red-cell fraction. It is very difficult to compare these results with what we have reported here, since our study was done with ANF-(Ser-99-Tyr-126), the circulating form of ANF, whereas the material used by the above-mentioned workers was a partially purified ANF preparation probably containing more than one peptide species. However, this extremely slow degradation of ANF (about 10-15 % in 30 min) would suggest that blood does not contribute to any great extent in the degradation of ANF.
Vascular tissue of the rat is known to contain a large number of high-affinity binding sites for ANF peptides [29, 30] . Since the vascular tissue has a very large surface area and ANF-(Ser-99-Tyr-126) has been shown to be a circulating hormone, it was of interest to study its degradation in a vascular bed. Isolated mesenteric-artery preparation was used as a model system to study this process. Preliminary studies indicated an initial rapid wash-out of a major portion of the injected radioactivity. This was followed by a gradual release of radioactive material from the tissue. Since this was a single-passage system, the gradual release of radioactive material may indicate a possible binding followed by internalization and a subsequent release of either the intact peptide or one of its degraded forms. Reverse-phase h.p.l.c. analysis of samples collected at different time intervals after injection of radiolabelled peptide, however, indicated degradation to be taking place. The degradation product was eluted at the same position as in the studies in vivo, suggesting that the product formed in both these studies was very similar.
Peptide hormones are known to interact first with membrane receptors on the cell surface and subsequently to be degraded, one of the major pathways being degradation after internalization in the target cell. In this pathway, the peptide hormones are internalized by receptor-mediated endocytosis, followed by degradation in the lysosomes [31, 32, 33] . Degradation of insulin by adipocytes [34, 35] and of epidermal growth factor by either human fibroblasts [36] or GH4C1 cells (a clonal strain of rat pituitary tumour cells) [37] are good examples of this process. However, somatostatin degradation in the GH4C1 cells does not follow this pathway, and it is degraded by some membrane-bound proteinases after binding to specific receptors on the cell surface [38] . In our study, since there is no recirculation of the sample through the tissue, degradation is likely to be taking place by either of the above-mentioned pathways. However, from our results it is difficult to say which of these processes is important in ANF degradation. In an earlier study on ANF degradation by rat vascular smooth-muscle cells in culture, Hirata et al. [38] have shown internalization of the 28-amino-acid peptide to precede degradation. It is quite likely that this pathway plays a major role in the degradation of this potent natriuretic peptide.
In conclusion, it could be said that ANF is eliminated from the circulation of the rat by a combination of binding and degradation. The biologically active 28-amino-acid peptide is converted into a short C-terminal fragment in the course of its circulation. Incubation studies with whole blood and plasma indicate that blood does not play a major role in ANF degradation. The 28-amino-acid peptide ANF-(Ser-99-Tyr-126) is, however, converted into a 24-amino-acid species, ANF-(Ser-l0-Tyr-126), in an extremely slow process. Isolated mesenteric artery appears to degrade ANF in a manner very similar to the degradation observed in vivo. This study also suggests that degradation occurs either after internalization of the peptide into the vascular smoothmuscle cells or by some membrane-bound enzyme in the vasculature. Further work is needed to substantiate this hypothesis.
